Bausch Health Companies Management
Management criteria checks 2/4
Actualmente no disponemos de información suficiente sobre el Director General.
Key information
Tom Appio
Chief executive officer
US$13.2m
Total compensation
| CEO salary percentage | 7.6% |
| CEO tenure | no data |
| CEO ownership | 0.1% |
| Management average tenure | 2.3yrs |
| Board average tenure | 8yrs |
Recent management updates
Recent updates
Bausch Health: A Timely Divestiture Is The Key To An Higher Valuation
Feb 24Bausch Health: $20bn Debt Is A Mighty Elephant In The Room
Nov 30Does Bausch Health Companies (NYSE:BHC) Have A Healthy Balance Sheet?
Nov 01
Bausch Health's Debt Dilemma: Strategic Decisions And Financial Metrics
Sep 24Is Bausch Health Companies (NYSE:BHC) A Risky Investment?
Jul 24Bausch + Lomb: $2.5bn M&A Deal Shows It Hasn't Learned From Parent's Mistakes
Jul 06What To Do After Bausch Health Stock Plunged By Nearly 9% Again
Jun 07Bausch Health Companies (NYSE:BHC) Has No Shortage Of Debt
Apr 18Bausch Health: A Basket Case Of A Business Only A Hedge Fund Can Bail Out
Dec 30Bausch Health acne lotion Arazlo available in Canada under public drug plans
Dec 22Bausch Health: Things To Consider Before Investing
Dec 11Bausch Health Companies (NYSE:BHC) Strong Profits May Be Masking Some Underlying Issues
Nov 10Bausch Health Companies Q3 2022 Earnings Preview
Nov 02Bausch Health: Long-Term Need To Place Stops For Protection
Sep 28Bausch Health Companies: Equity Stub Would Benefit From Ambitious Spinoff
Sep 21Bausch Health sheds 10% as FDA grants tentative approval for Xifaxan generic
Sep 08Bausch Health begin offers to exchange debt up to $4B
Aug 31Bausch Health Stock Down 11%: Now What?
Aug 09Bausch Health: How To Price The Calamities
Jul 31Bausch Health: Uncertain, Far From Healthy, But Potentially Lucrative
Jul 18Bausch Health Stock Soared By 20%: What To Do Now
Jun 27CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -US$592m |
| Sep 30 2023 | n/a | n/a | -US$963m |
| Jun 30 2023 | n/a | n/a | -US$186m |
| Mar 31 2023 | n/a | n/a | -US$357m |
| Dec 31 2022 | US$13m | US$1m | -US$225m |
| Sep 30 2022 | n/a | n/a | US$254m |
| Jun 30 2022 | n/a | n/a | US$43m |
| Mar 31 2022 | n/a | n/a | -US$407m |
| Dec 31 2021 | US$10m | US$854k | -US$948m |
| Sep 30 2021 | n/a | n/a | -US$1b |
| Jun 30 2021 | n/a | n/a | -US$1b |
| Mar 31 2021 | n/a | n/a | -US$1b |
| Dec 31 2020 | US$4m | US$775k | -US$560m |
| Sep 30 2020 | n/a | n/a | -US$2b |
| Jun 30 2020 | n/a | n/a | -US$2b |
| Mar 31 2020 | n/a | n/a | -US$2b |
| Dec 31 2019 | US$4m | US$769k | -US$2b |
| Sep 30 2019 | n/a | n/a | -US$616m |
| Jun 30 2019 | n/a | n/a | -US$917m |
| Mar 31 2019 | n/a | n/a | -US$2b |
| Dec 31 2018 | US$4m | US$730k | -US$4b |
| Sep 30 2018 | n/a | n/a | -US$3b |
| Jun 30 2018 | n/a | n/a | -US$2b |
| Mar 31 2018 | n/a | n/a | -US$805m |
| Dec 31 2017 | US$3m | US$650k | US$2b |
Compensación vs. Mercado: Tom($USD13.17M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD6.59M).
Compensación vs. Ingresos: La compensación de Tom ha aumentado mientras la empresa no es rentable.
CEO
Tom Appio (61 yo)
no data
Tenure
US$13,171,461
Compensation
Mr. Thomas J. Appio, also known as Tom, serves as the Chief Executive Officer & Director at Bausch Health Companies Inc. and served as Chief Executive Officer of Pharma Business and served as President & C...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | no data | US$13.17m | 0.10% $ 3.9m | |
| Executive VP & General Counsel | 2.3yrs | US$4.21m | 0.023% $ 853.2k | |
| Senior VP | 2.3yrs | no data | 0.0045% $ 169.2k | |
| Senior VP & COO | 2.3yrs | no data | 0.024% $ 910.9k | |
| Senior Vice President of Sales & Salix | 1.3yrs | no data | no data | |
| Senior VP & Chief HR Officer | 2.3yrs | no data | no data | |
| Chief Medical Officer and President of R&D | no data | no data | no data | |
| Executive VP of Market Access | 3.8yrs | no data | no data | |
| Senior VP & Chief Quality Officer | 2.3yrs | no data | no data | |
| Senior Vice President of Europe & Canada | 2.3yrs | no data | no data | |
| Senior Vice President of Ortho Dermatologics | no data | no data | no data | |
| Senior Vice President of Solta Medical | 1.3yrs | no data | no data |
2.3yrs
Average Tenure
50yo
Average Age
Equipo directivo experimentado: BHCEl equipo directivo de la empresa se considera experimentado (2 años de antigüedad media).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | no data | US$13.17m | 0.10% $ 3.9m | |
| Lead Independent Director | 8.1yrs | US$752.30k | 0.0032% $ 117.4k | |
| Independent Chairman | 1.8yrs | US$701.74k | 0.000060% $ 2.2k | |
| Independent Director | 15.7yrs | US$399.15k | 0.0018% $ 67.5k | |
| Chairman of External Advisory Board | no data | US$2.00m | no data | |
| Independent Director | 7.8yrs | US$698.89k | 0% $ 0 | |
| Member of the External Advisory Board | 15.1yrs | no data | no data | |
| Member of the External Advisory Board | 15.1yrs | no data | no data | |
| Member of the External Advisory Board | 15.1yrs | no data | no data | |
| Independent Director | 7.8yrs | US$679.58k | 0% $ 0 | |
| Independent Director | 7.8yrs | US$377.50k | no data | |
| Independent Director | 3.1yrs | US$370.69k | 0.019% $ 698.5k |
8.0yrs
Average Tenure
68yo
Average Age
Junta con experiencia: La junta directiva de BHC se considera experimentada (7.6 años de antigüedad promedio).